Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPD3310 in Advanced Malignant Solid Tumors
NCT07368127Phase 1Recruiting
- Sponsor
- Taibidi Pharmaceutical Technology
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TPD3310 in solid tumor, sponsored by Taibidi Pharmaceutical Technology. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose at 1 year and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
TPD3310
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07368127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07368127.